The Eastern Cooperative Oncology Group (ECOG) is a multidisciplinary cancer clinical trials research group dedicated to the treatment, prevention, and cure of adult malignancies. The Operations Office grant application requests funding to support the activities of the group headquarters. Under the direction of the Principal Investigator, Robert L. Comis, MD, the ECOG Operations office is responsible for organizing and coordinating the scientific and administrative activities of the Group;these activities include protocol development, correlative study development, dissemination of necessary information to Group members, organization of Group meetings, maintenance of Group membership and publications, monitoring of compliance with regulatory requirements, adverse event (AE) reporting and review, administration of the audit program, the development and maintenance of standard operating procedures (SOPs), and the management and disbursement of Group funds. Funding requested by the ECOG Operations Office Grant includes support for the Chairs of the ECOG Scientific and Administrative Committees. Additionally funding is requested in this application for member institution accruals to therapeutic and non-therapeutic clinical trials. This application requests funding for the period 05/01/2010 - 04/30/2016.

Public Health Relevance

The primary goal of the ECOG Operations Office is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA021115-38
Application #
8307011
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1992-09-01
Project End
2016-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
38
Fiscal Year
2012
Total Cost
$8,790,165
Indirect Cost
$1,423,951
Name
Frontier Sci & Technology Rsch Fdn, Inc
Department
Type
DUNS #
080330186
City
Boston
State
MA
Country
United States
Zip Code
02215
Tevaarwerk, Amye J; Lee, Ju-Whei; Terhaar, Abigail et al. (2016) Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. Cancer 122:438-46
Hertz, Daniel L; Owzar, Kouros; Lessans, Sherrie et al. (2016) Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res 22:4890-4900
Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Kenkre, Vaishalee P; Hong, Fangxin; Cerhan, James R et al. (2016) Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clin Cancer Res 22:821-6
Burtness, Barbara; Powell, Mark; Catalano, Paul et al. (2016) Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 39:340-5
Jacobus, S J; Rajkumar, S V; Weiss, M et al. (2016) Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J 6:e448
Luskin, Marlise R; Lee, Ju-Whei; Fernandez, Hugo F et al. (2016) Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 127:1551-8
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75

Showing the most recent 10 out of 691 publications